179 related articles for article (PubMed ID: 33610480)
1. Impact of contracted manufacturing organization protocols on operations in an aca demically based Current Good Manufacturing Practice facility.
Sutherland V; Buffo MJ; Whiteside TL
Cytotherapy; 2022 Jan; 24(1):32-36. PubMed ID: 33610480
[TBL] [Abstract][Full Text] [Related]
2. Accommodating clinical trials and other externally manufactured cellular therapy products: challenges, lessons learned and creative solutions.
Jackson MR
Cytotherapy; 2022 Jan; 24(1):37-44. PubMed ID: 34305008
[TBL] [Abstract][Full Text] [Related]
3. National Survey of FACT-Accredited Cell Processing Facilities: Assessing Preparedness for Local Manufacturing of Immune Effector Cells.
Elsallab M; Bourgeois F; Maus MV
Transplant Cell Ther; 2024 Jun; 30(6):626.e1-626.e11. PubMed ID: 38494077
[TBL] [Abstract][Full Text] [Related]
4. Challenges and advantages of cell therapy manufacturing under Good Manufacturing Practices within the hospital setting.
Iancu EM; Kandalaft LE
Curr Opin Biotechnol; 2020 Oct; 65():233-241. PubMed ID: 32663771
[TBL] [Abstract][Full Text] [Related]
5. Proceedings of the first academic symposium on developing, qualifying and operating a cell and gene therapy manufacturing facility.
Digiusto DL; Melsop K; Srivastava R; Tran CT
Cytotherapy; 2018 Dec; 20(12):1486-1494. PubMed ID: 30377039
[TBL] [Abstract][Full Text] [Related]
6. Place of Academic GMP Facilities in Modern Cell Therapy.
Bersenev A; Fesnak A
Methods Mol Biol; 2020; 2097():329-339. PubMed ID: 31776936
[TBL] [Abstract][Full Text] [Related]
7. Healthcare center-based cell therapy laboratories supporting off-site manufactured cell therapies: The experiences of a single academic cell therapy laboratory.
Dinh A; Stroncek DF
Transfusion; 2024 Feb; 64(2):357-366. PubMed ID: 38173340
[TBL] [Abstract][Full Text] [Related]
8. Operation of a radiopharmacy for a clinical trial.
Norenberg JP; Petry NA; Schwarz S
Semin Nucl Med; 2010 Sep; 40(5):347-56. PubMed ID: 20674594
[TBL] [Abstract][Full Text] [Related]
9. Processing laboratory considerations for multi-center cellular therapy clinical trials: a report from the Consortium for Pediatric Cellular Immunotherapy.
Lindgren C; Leinbach A; Annis J; Tanna J; Zhang N; Esensten JH; Hanley PJ
Cytotherapy; 2021 Feb; 23(2):157-164. PubMed ID: 33189573
[TBL] [Abstract][Full Text] [Related]
10. Sterility Testing for Cellular Therapies: What Is the Role of the Clinical Microbiology Laboratory?
Gebo JET; Lau AF
J Clin Microbiol; 2020 Jun; 58(7):. PubMed ID: 32321785
[TBL] [Abstract][Full Text] [Related]
11. Biopharmaceutical Industry Approaches to Facility Segregation for Viral Safety: An Effort from the Consortium on Adventitious Agent Contamination in Biomanufacturing.
Barone PW; Avgerinos S; Ballard R; Brussel A; Clark P; Dowd C; Gerentes L; Hart I; Keumurian FJ; Kindermann J; Leung JC; Ly N; Mink S; Minning S; Mullberg J; Murphy M; Nöske K; Parriott S; Shum B; Wiebe ME; Springs SL
PDA J Pharm Sci Technol; 2019; 73(2):191-203. PubMed ID: 30361281
[TBL] [Abstract][Full Text] [Related]
12. What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings.
Ten Ham RMT; Hövels AM; Hoekman J; Frederix GWJ; Leufkens HGM; Klungel OH; Jedema I; Veld SAJ; Nikolic T; Van Pel M; Zwaginga JJ; Lin F; de Goede AL; Schreibelt G; Budde S; de Vries IJM; Wilkie GM; Dolstra H; Ovelgönne H; Meij P; Mountford JC; Turner ML; Hoefnagel MHN
Cytotherapy; 2020 Jul; 22(7):388-397. PubMed ID: 32414635
[TBL] [Abstract][Full Text] [Related]
13. Management of externally manufactured cell therapy products: the Mayo Clinic approach.
Wiltshire TD; Deeds MC; Radel DJ; Bornschlegl AM; Schmidt CS; Thebiay JM; Pelleymounter LL; Jacob EK; Stubbs JR; Gastineau DA; Dietz AB
Cytotherapy; 2022 Jan; 24(1):19-26. PubMed ID: 34980364
[TBL] [Abstract][Full Text] [Related]
14. Raising the standard: changes to the Australian Code of Good Manufacturing Practice (cGMP) for human blood and blood components, human tissues and human cellular therapy products.
Wright C; Velickovic Z; Brown R; Larsen S; Macpherson JL; Gibson J; Rasko JE
Pathology; 2014 Apr; 46(3):177-83. PubMed ID: 24614714
[TBL] [Abstract][Full Text] [Related]
15. First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--Chapter 3: Porcine islet product manufacturing and release testing criteria.
Rayat GR; Gazda LS; Hawthorne WJ; Hering BJ; Hosking P; Matsumoto S; Rajotte RV
Xenotransplantation; 2016; 23(1):38-45. PubMed ID: 26923763
[TBL] [Abstract][Full Text] [Related]
16. A multiscale simulation framework for the manufacturing facility and supply chain of autologous cell therapies.
Wang K; Liu Y; Li J; Wang B; Bishop R; White C; Das A; Levine AD; Ho L; Levine BL; Fesnak AD
Cytotherapy; 2019 Oct; 21(10):1081-1093. PubMed ID: 31445816
[TBL] [Abstract][Full Text] [Related]
17. How we manage clinical trials in the cellular therapy laboratory.
Tanhehco YC; Schwartz J
Transfusion; 2018 Jan; 58(1):8-15. PubMed ID: 28940293
[No Abstract] [Full Text] [Related]
18. The implementation of tissue banking experiences for setting up a cGMP cell manufacturing facility.
Arjmand B; Emami-Razavi SH; Larijani B; Norouzi-Javidan A; Aghayan HR
Cell Tissue Bank; 2012 Dec; 13(4):587-96. PubMed ID: 21870140
[TBL] [Abstract][Full Text] [Related]
19. Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies.
Abbasalizadeh S; Baharvand H
Biotechnol Adv; 2013 Dec; 31(8):1600-23. PubMed ID: 23962714
[TBL] [Abstract][Full Text] [Related]
20. Will regulation be the death of cell therapy in the United States?
Gastineau DA
Bone Marrow Transplant; 2004 Apr; 33(8):777-80. PubMed ID: 14968138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
